We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Respiratory Syncytial Virus Bronchiolitis Has Different Subtypes

By LabMedica International staff writers
Posted on 30 Jun 2021
Bronchiolitis is the leading cause of hospitalization in infants in the USA, accounting for about 110,000 hospitalizations annually. More...
In addition to the substantial acute morbidity, around 30% of infants hospitalized for bronchiolitis (“severe bronchiolitis”) subsequently develop asthma in childhood.

Of the major causative pathogens, respiratory syncytial virus (RSV) infection during infancy has the largest population attributable fraction. While bronchiolitis has been considered a single disease with similar mechanisms, emerging evidence suggests heterogeneity in clinical presentations and chronic morbidities (e.g., subsequent risk of recurrent wheeze and asthma).

Medical Scientists at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues analyzed the data from a multicenter prospective cohort study of infants hospitalized for bronchiolitis. This prospective cohort study completed enrollment of 1,016 infants (age < 1 year) hospitalized with bronchiolitis at 17 sites across 14 USA states. Of these 1,016 infants (median age, 3 months; female, 40%), 921 (91%) completed the run-in procedure.

The team isolated total RNA from the nasopharyngeal samples using Trizol LS reagent (ThermoFisher Scientific, Waltham, MA, USA) in combination with the Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA, USA). RNA quantity was measured with the (ThermoFisher Scientific Qubit 2.0 fluorometer and its quality was assessed with the Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using the RNA 6000 Nano kit.

To provide further insights, the team analyzed diverse clinical, genetic, and molecular data from 221 infants hospitalized with RSV bronchiolitis who were followed until age 5 years. They gathered information on the viruses that had infected the children, as well as information on the microbes, metabolites, and immune response-related molecules present in the children’s nasal passages.

The scientists reported that based on their analyses, four biologically and clinically meaningful subtypes, or endotypes, of RSV bronchiolitis exist. Of these, 1 endotype, which is characterized by coinfection by rhinovirus, dominance by specific bacteria, and high interferon (IFN) response, had an approximate 40% risk of developing asthma by age five.

The investigators identified four biologically- and clinically-meaningful endotypes: “(1) clinicalclassicmicrobiomeM nonliquefaciensinflammationIFN-intermediate; (2) clinicalatopicmicrobiomeS pneumoniae/M catarrhalisinflammationIFN-high; (3) clinicalseveremicrobiomemixedinflammationIFN-low; and (4) clinicalnon-atopicmicrobiomeM.catarrhalisinflammationIL-6. Particularly, compared with endotype A infants, endotype B infants, had a significantly higher risk for developing asthma (9% versus 38%).

Yoshihiko Raita, MD, an Emergency Medicine physician and first author of the study, said, “Our data add significant support to the emerging concept that bronchiolitis represents several diseases with unique biological mechanisms. For clinicians, our findings give an evidence base for the early identification of high-risk children during an important period of airway development, early infancy.

The authors concluded that by applying an integrated omics approach to data from a multicenter prospective cohort study of 221 infants with RSV bronchiolitis, they had identified four biologically distinct and clinically meaningful endotypes. The study was published on June 14, 2021, in the journal Nature Communications.


Related Links:
Massachusetts General Hospital
ThermoFisher Scientific
Zymo Research
Agilent



Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.